The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Cohort Study Reveals Patients Treated with Rituximab Have Poorer COVID-19 Outcomes

Cohort Study Reveals Patients Treated with Rituximab Have Poorer COVID-19 Outcomes

June 7, 2021 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

When the investigators compared hospital stays of patients who received rituximab and those who did not, they observed a prolonged hospital stay and increased risk of morbidity, mortality and potential infection-related sequelae. Although more patients treated with rituximab died, after the researchers adjusted for potential confounders, they found the risk of death did not increase significantly compared with patients not treated with rituximab, reinforcing to the authors the importance of associated comorbidities.

You Might Also Like
  • COVID-19 Outcomes in Patients with Rheumatic Disease
  • Rheumatoid Arthritis Patients Have More Severe ACS, Poorer Outcomes
  • Race Matters in COVID-19 Outcomes for Patients with Rheumatic Disease
Also By This Author
  • Lungs Are Particularly Vulnerable in Patients with Systemic Rheumatic Disease

The authors conclude by suggesting it may be wise to delay rituximab therapy in patients with rheumatoid arthritis. However, they note the decision to delay therapy may be more difficult in patients with connective tissue disorders or vasculitis, who are at risk greater risk of disease relapse.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Additionally, Dr. Calabrese says the findings have implications for the timing and choice of COVID-19 vaccine. It appears vaccines given within five months of the last rituximab dose are not as effective. Therefore, if possible, experts recommend giving the COVID-19 vaccine at least four to six months after the last infusion and four to six weeks before the next infusion.3 Likewise, administering a two-dose vaccine may be more challenging to coordinate for patients who are due for their rituximab therapy than a single-dose vaccine. It may not be feasible for patients to delay their treatment.

“This study confirms the importance of timing of vaccines in patients receiving rituximab, especially because this group also has increased risk of poor outcomes if infected with SARS-CoV-2,” Dr. Calabrese says.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

References

  1. FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: Data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis. 2020 Dec 2;80(4):527–538. Online ahead of print.
  2. Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: A cohort study. Lancet Rheumatol. 2021 Mar 25. Online ahead of print.
  3. Dougados M. Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic. Lancet Rheumatol. 2021 Jun;3(6):e395–e396. Epub 2021 Mar 25.

Pages: 1 2 | Single Page

Filed Under: Conditions Tagged With: COVID-19, Outcomes, rituximab

You Might Also Like:
  • COVID-19 Outcomes in Patients with Rheumatic Disease
  • Rheumatoid Arthritis Patients Have More Severe ACS, Poorer Outcomes
  • Race Matters in COVID-19 Outcomes for Patients with Rheumatic Disease
  • Tocilizumab Fails to Help COVID-19 Patients in Italian Study

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)